We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+20.56%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$227M
AUM Growth
-$13.1M
Cap. Flow
-$40.4M
Cap. Flow %
-17.78%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ATXS
Astria Therapeutics
ATXS
+$34.7M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$72.3M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$2.76M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIEN
1
DELISTED
Sientra, Inc.
SIEN
$68.9M 30.3%
273,077
– –
NSTG
2
DELISTED
NanoString Technologies, Inc.
NSTG
$61.1M 26.85%
3,959,440
– –
ATXS
3
DELISTED
Astria Therapeutics
ATXS
$33.6M 14.78%
+45,875
New +$34.7M
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$30M 13.2%
2,167,377
-203,951
-9% -$2.76M
VBIV
5
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$13.3M 5.86%
165,703
– –
TLOG
6
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$10.9M 4.78%
4,644,705
– –
EVFM
7
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$9.64M 4.24%
11,905
– –
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,554,744
Closed -$72.3M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q2 2015 Portfolio in Review

As of Q2 2015, Clarus Ventures held 8 positions worth $227M, down 5.5% from $241M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures withdrew a net $40.4M in Q2 2015, closing 1 position and reducing 1 holding. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $72.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Clarus Ventures opened a new position in Astria Therapeutics worth $33.6M.

  • Clarus Ventures's largest Q2 2015 buy was Astria Therapeutics: 45,875 shares worth $33.6M.
  • Clarus Ventures's biggest Q2 2015 reduction was Oxford Immunotec Global PLC Ordinary Shares, cutting an estimated $2.76M.
  • Clarus Ventures fully exited IVERIC bio, Inc. Common Stock in Q2 2015, selling an estimated $72.3M.
  • Clarus Ventures's ten largest holdings make up 100% of its $227M portfolio in Q2 2015.
  • Clarus Ventures opened 1 new position and closed 1 in Q2 2015.
  • Clarus Ventures's portfolio value fell 5.5% quarter-over-quarter to $227M.

Based on Clarus Ventures's 13F filing for Q2 2015, filed 30 Jul 2015.